Prevalence and incidence of co-morbid lung disease associated with type 2 diabetes from the UK Biobank

Abstract

Aim: This analysis examined the prevalence and incidence of type 2 diabetes mellitus (T2DM) and co-morbid lung disease in the UK Biobank population. Methods: Non-communicable inflammatory lung diseases, body mass index (BMI), age, glycated haemoglobin (HbA1c), sex, smoking status, diabetes status, forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) data were obtained. Participants were categorised by BMI: lean (18.5–24.9 kg/m²), overweight (25–29.9 kg/m²), and obese (≥ 30 kg/m²). Fisher’s exact test identified lung disease prevalence and incidence. Kruskal-Wallis assessed lung function variance and its correlation with HbA1c. Cox regression analysed the impact of confounders on time to lung disease events. Results: Overweight and obesity increased the prevalence and incidence of chronic obstructive pulmonary disease, asthma, and bronchitis, but this was not evident in cases of bronchiectasis in those without T2DM (P ＜ 0.05–0.0001). Conversely, T2DM increased lung disease risk across all BMIs (P ＜ 0.0001) and reduced FEV1 and FVC even after HbA1c normalisation (P ＜ 0.0001). FEV1 and FEV1/FVC were negatively correlated with HbA1c. Age, diabetes, being a woman, smoking, reduced FEV1 and FEV1/FVC ratio, but not BMI, were factors in lung disease development in T2DM. Conclusions: Inflammatory lung conditions are more common in T2DM patients, regardless of BMI. The pattern of lung decline suggests restrictive impairment, despite a high risk of obstructive disorders. This data adds to the evidence that the lungs are a target organ of diabetes damage.

Keywords

Diabetes / obesity / body mass index (BMI) / lung disease / UK Biobank / prevalence

References

[1] Pitocco D, Fuso L, Conte EG, Zaccardi F, Condoluci C, Scavone G, et al. The diabetic lung--a new target organ? Rev Diabet Stud. 2012; 9: 23-35.

[2] Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: findings from the British Women’s Heart and Health Study. Diabetologia. 2004; 47: 195-203.

[3] Shah SH, Sonawane P, Nahar P, Vaidya S, Salvi S. Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India. 2013; 30: 108-12.

[4] Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, Shan J, Ferrara A. Patients Diagnosed With Diabetes Are at Increased Risk for Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, and Pneumonia but Not Lung Cancer. Diabetes Care. 2010; 33: 55-60.

[5] Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol. 2005; 115: 897-909.

[6] Ofulue AF, Thurlbeck WM. Experimental diabetes and the lung: II. In vivo Connective Tissue Metabolism. Am Rev Respir Dis. 1988; 138: 284-9.

[7] Kolahian S, Leiss V, Nürnberg B. Diabetic lung disease: fact or fiction? Rev Endocr Metab Disord. 2019; 20: 303-19.

[8] Varun K, Zoltan K, Alba S, Manuel B, Elisabeth K, Dimitrios T, et al. Elevated markers of DNA damage and senescence are associated with the progression of albuminuria and restrictive lung disease in patients with type 2 diabetes. EBioMedicine. 2023; 90: 104516.

[9] The R Project for Statistical Computing [Internet]. R Foundation; [cited 2023 Oct 27]. Available from: https://www.R-project.org/

[10] Hanscombe KB, Coleman JRI, Traylor M, Lewis CM. ukbtools: An R package to manage and query UK Biobank data. PLoS One. 2019; 14: e0214311.

[11] The most trusted IDE for open source data science [Internet]. Boston: Posit Software, PBC formerly RStudio, PBC; c2025 [cited 2023 Oct 27]. Available from: https://posit.co/products/open-source/rstudio/

[12] Defining a model for Cox proportional hazards regression [Internet]. GraphPad Software, LLC.; c1995-2025 [cited 2023 Oct 27]. Available from: https://www.graphpad.com/guides/prism/latest/statistics/stat_cox_regression_model_tab.htm

[13] Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006; 23: 469-80.

[14] Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022; 60: 2101499.

[15] Lee JM, Lee SA, Han CH, Lee SM, Kim CJ, Lee SC, et al. Body mass index as a predictor of mortality in bronchiectasis: A nationwide population-based study. Respir Med. 2021; 180: 106370.

[16] Wang X, Balaña-Corberó A, Martínez-Llorens J, Qin L, Xia Y, Zha J, et al. Respiratory and Peripheral Muscle Weakness and Body Composition Abnormalities in Non-Cystic Fibrosis Bronchiectasis Patients: Gender Differences. Biomedicines. 2022; 10: 334.

[17] Khateeb J, Fuchs E, Khamaisi M. Diabetes and Lung Disease: A Neglected Relationship. Rev Diabet Stud. 2019; 15: 1-15.

[18] Del Pino-Sedeño T, González de León B, Pérez Martín EF, Martín Gandolfo AM, Estupiñán Ramírez M, Redondo M, et al. Relationship between glycemic control and chronic obstructive pulmonary disease in patients with type 2 diabetes: A nested case-control study. Prim Care Diabetes. 2020; 14: 729-35.

[19] Sherman CB. The health consequences of cigarette smoking. Pulmonary diseases. Med Clin North Am. 1992; 76: 355-75.

[20] Cho SJ, Stout-Delgado HW. Aging and Lung Disease. Annu Rev Physiol. 2020; 82: 433-59.

[21] Suastika K, Dwipayana P, Siswadi MS, Kuswardhani TRA. Age is an Important Risk Factor for Type 2 Diabetes Mellitus and Cardiovascular Diseases. In: Glucose Tolerance. InTech; 2012.

[22] Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. Transl Res. 2017; 184: 101-7.

[23] Nordström A, Hadrévi J, Olsson T, Franks PW, Nordström P. Higher Prevalence of Type 2 Diabetes in Men Than in Women Is Associated With Differences in Visceral Fat Mass. J Clin Endocrinol Metab. 2016; 101: 3740-6.

[24] Ciarambino T, Crispino P, Leto G, Mastrolorenzo E, Para O, Giordano M. Influence of Gender in Diabetes Mellitus and Its Complication. Int J Mol Sci. 2022; 23: 8850.

[25] Silveyra P, Fuentes N, Rodriguez Bauza DE. Sex and Gender Differences in Lung Disease. Adv Exp Med Biol. 2021; 1304: 227-58.

[26] van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a metaanalysis. Chest. 2010; 138: 393-406.

[27] Wang MY, Yang J, Ke H, Wang B, Liang BM, Ou XM, et al. Association of chronic obstructive pulmonary disease with type 2 diabetes mellitus. Chin Med J (Engl). 2014; 127: 3185-6.

[28] Liu J, Song X, Zheng S, Ding H, Wang H, Sun X, et al. A prospective study on physical performance of Chinese chronic obstructive pulmonary disease males with type 2 diabetes. Medicine (Baltimore). 2021; 100: e27126.

[29] Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014; 30: 96-102.

[30] Kalhan SC, Adam PA. Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration. J Clin Endocrinol Metab. 1975; 41: 600-10.

[31] Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017; 186: 1026-34.